Non-Small-Cell Lung/drug therapy
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer
... of cell lines spanning multiple cancer types to ...that cell lines with high expression of BIM are highly sensitive to ABT-263 and that SCLC expresses higher levels of BIM than other solid tumor ...either ...
10
The increasing role of amphiregulin in non-small cell lung cancer.
... Abstract Non-small cell lung cancers present a 5-year survival rate below ...by non small cell lung cancer cells evasion to apoptosis and resistance to ...by ...
10
A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer
... possible drug interactions with indisulam, patients were excluded if they had received any of the following drugs within 2 weeks of enrollment: coumarin anticoagulants, terfenadine, cisapride, ...
10
Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients
... and non-smokers at cancer diagnosis and show- ing that smoking caused worse response to CT and shorter survival [ 18 ...in non-smokers (19%) than in former smokers (8%) or in current smokers (12%) (p = ...
14
Visual Versus Quantitative Assessment of Intratumor 18F-FDG PET Uptake Heterogeneity: Prognostic Value in Non-Small Cell Lung Cancer.
... 5. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012;264(2):559 –66. 6. ...
29
A rare case of palatin tonsillar metastasis from small cell lung cancer
... al. Small cell lung cancer with palatin tonsillar metastasis © Translational lung cancer ...Transl Lung Cancer Res 2016;5(6):709-711 cells spreading to tonsil remains ...stem-like ...
3
Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines
... EDTA 1 mM, Nonidet P-40 0.5 %, NaF 1 mM, Na 3 VO 4 1 mM, phenylmethylsulfonyl fluoride (PMSF) 0.5 mM, leupeptin 10 µg/ml, aprotinin 10 µg/ml and pepstatin 10 µg/ml) for 30 min on ice. Protein content was assessed by the ...
36
BMI1 is a context-dependent tumor suppressor that is a barrier to dedifferentiation in non-small cell lung adenocarcinoma
... sporadic lung cells, many of which undergo malignant transformation and give rise to LUAD tumors with variable latency, resulting in a wide spectrum of tumor grades at later time ...
139
EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung Carcinomas
... the cell type and could function, at least partially, independently of the ...squamous cell carcinoma cell lines, and the inhibition of its expression repressed the expression of mesenchymal markers ...
23
Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC).
... by lung cancer cells and is detectable in patient's serum (Ishikawa et al, ...from lung cancer patients produce elevated levels of mature TNF-α (Trejo et al, 2001) which could result from the shedding of ...
12
Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer
... with lung tumor stroma activation To explore the association of PAR-1 expression with the NSCLC stroma, we correlated PAR-1 gene expression levels with specific markers of different stromal cell types, ...
9
Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC)
... Conclusion So far to our knowledge, our study is the first to assess the clinical impact of WT and variant forms of HLTF expression in patients with NSCLC. TCGA in silico analysis of HLTF alterations including mutations, ...
11
Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma
... Figure 5. E2F1, cyclin A, cyclin E, DHRF and cdc2 protein expressions in normal lung tissues (A), SCLC (B), adenocarcinoma (C) and squamous carcinoma (D). Western-blot analysis was performed as described in ...
24
Quality of life after the initial treatments of non-small cell lung cancer: a persistent predictor for patients' survival.
... However, this time period may introduce some selection bias because some patients had died or were lost to follow-up before HRQoL measurement. Patients who did not make it until a 3 month follow-up were older and mostly ...
11
Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer
... L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ...
38
Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma: E2F1 expression in human lung tumours
... Figure 5. E2F1, cyclin A, cyclin E, DHRF and cdc2 protein expressions in normal lung tissues (A), SCLC (B), adenocarcinoma (C) and squamous carcinoma (D). Western-blot analysis was performed as described in ...
29
Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.: Areg and gefitinib resistance in NSCLC
... Human lung adenocarcinoma H358 cells were harvested, and 20x10 6 cells in PBS were injected subcutaneously into the flank of female NMRI nude mice (6-8 weeks old, Janvier, Le Genest Saint Isle, ...
34
Characterisation of gut, lung, and upper airways microbiota in patients with non-small cell lung carcinoma Study protocol for case-control observational trial Study Protocol Clinical Trial
... before therapy had signi ficantly decreased overall and progression-free ...to therapy were performed, inoculated germ-free (GF) mice showed the same phenomenon during ICI therapy against MCA-205 ...
13
Sleeve lobectomy may provide better outcomes than pneumonectomy for non-small cell lung cancer. A decade in a nationwide study
... R1 R2 Missing Characteristics of Center Type of center Non-Academic Private Academic ...
36
Phase II trial exploring gemcitabine and cisplatin as treatment of patients with non-small cell lung cancer (NSCLC) and inoperable brain metastases
... ’ EC Cancer Agency Surrey, Canada; ’ BC Cancer Agency Vancouver, Canada; 3 BC Cancer Agency Nanaimo, Canada; 4 SC Cancer Agenq Victoria, Canada; 5BC Cancer Agency [r] ...
1